In the recent phase I/II study by Liu et al., 11 patients with CD19+ hematologic malignancies (relapsed or refractory) were administered HLA-mismatched anti-CD19 CAR-NK cells derived from UCB (119). Here, CD19 is linked to hematologic disorder.